{
  "directed": true,
  "multigraph": true,
  "graph": {
    "pybel_version": "0.13.1",
    "document_metadata": {
      "copyright": "Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved",
      "licenses": "CC BY-SA 4.0",
      "contact": "rana.al.disi@scai.fraunhofer.de",
      "name": "francis2016",
      "version": "1.0.0",
      "authors": "Rana Aldisi",
      "description": "this file encodes the article Interplay of neurotransmitters in Alzheimer's disease by Francis et al. 2016"
    },
    "namespace_url": {
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/1b20f0637c395f8aa89c2e2e342d7b704062c242/external/mesh.belns",
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/1b20f0637c395f8aa89c2e2e342d7b704062c242/external/chebi-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/1b20f0637c395f8aa89c2e2e342d7b704062c242/external/hgnc-symbols.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/1b20f0637c395f8aa89c2e2e342d7b704062c242/external/go.belns",
      "GFAM": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hgnc-gene-families/hgnc-gene-families-20170710.belns"
    },
    "namespace_pattern": {},
    "namespaces_uncached": [],
    "annotation_url": {
      "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
    },
    "annotation_pattern": {
      "Species": "\\d+"
    },
    "annotation_list": {},
    "path": "/Users/cthoyt/dev/hbp-knowledge/hbp_knowledge/francis2016.bel"
  },
  "nodes": [
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "NMDA receptor antagonist",
      "id": "4b8a86d1d301c21ac50c38a1980c2f2f7316a17853b1687990c429433521eb54fe71fb00d5f59ef71880ad51017f285bb0add2fd926057d4928bd50eb63b01ef"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "calcium(2+)",
      "id": "4fb8648e4c5fea95cea6a46291d28175bba677d8b6fa8d607b1febef51c8370cbc1ff98d09312dc418ff31d04177d26f231d4f0a1a963f43fbc29cfb3269d3c9"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "glutamate(1-)",
      "id": "fc1b84427efecfb8e3a837d65b6e115ffa8c7fc53ebacb54b967fd3aaafd25a6f47c147e986961e53c4ef1d5c36420fd9194019b5f81eeb5d33310f314818875"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "glutamate(2-)",
      "id": "9749d43ec7dd166b90348b70de96bca3f824fa7c4624aa5f0d82f2dbd2e1d559cccd5b7e74c86268f2e152cea542c1a7c99fc9b98d5d12853d44f9a56b615e4a"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "magnesium(2+)",
      "id": "5e2de80f196789c60a949cec716bb15f3f5b418c54919e7f81cfb6a8915ec12e154d6b6fa364751e8b8e5240f419f7dc76e4f27ec7ae56d57bb125a93f071f47"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "acetylcholine",
      "id": "bae5841bb74f1e9eb73cd433cda657927031217c24e17f21bb2975128d1d9be4dc899448ede71d9aa18224145a1681b90b33287454eabf938f405bc1b8894b62"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "glutamine",
      "id": "5cc3d01fd864192f5e36b69ba330199e2f542fc9ca26dd80ac376262bfa5314166886f131e63e168797d436401cfe0f532e2f4f48e008e5f58aaa873cb1bdcd9"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "memantine",
      "id": "a6417701f850dae3b77bc52ab06561523bf34757aa461d008c48b9b489cf2293a3fb2bd592ae99ac7d23dd6143614f12df64ef718109abeaf9651954c612bfe7"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "D002800",
      "id": "094d80a48e7aa7ca487de38c5a885c720dae5f211d4964b9765cfcb1ebe1b1dbc197bd9e013055ee61708c81e934675c46fb9e666ad4f870de958eb5c5d0ac3b"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "D006624",
      "id": "859ab4dc9020a17032ca4de234a24807ea1269d707e9ef299b23a5cd0ac15707138c477867b119265b268cb59752d9740b37ee8d78e7a293a73331a3d7854ddd"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "D009474",
      "id": "0cb08b8e6207326988d4402ed5a2c4be527f13e3c60f90d3febd917be7a4c20c79b42362f98864ed8f5c0099b19036445422656c25f8e490dab6abd59f32f497"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "D017966",
      "id": "1f7033fe4a9d977379475861b649e61ac7a44332f9db26d8eca1a7fa1b23ac58999c39e0d33bc61168a8d8dbf3970e86289d17f2ae213778c2fb74bdce32f126"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "D019579",
      "id": "717e0962962db7ccbaf5b090d3e4001a0f114429d70f88ec8d8aa631f3822b9b6f3ae50e908d30178c47a2a06c8f9d17112f41dc917f1472c88bf742a4f0351d"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "GO:0006868",
      "id": "372e08a389a469dc41c7e34822036dd36ffffb76291d85b7ad803cda6d80279984e6237e4733a4662531e713cb6e244cb49473f351fede1d87e40924e986f2a9"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "GO:0007271",
      "id": "19ad0be19cf8814cf03473c099dd36ec10002c5405d27730a6c2a68da5bb05017708a28031e4d434847b884ea7460b76f1348c5f5329e6003d912b5c72503827"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "GO:0008292",
      "id": "b413b70325bfe7734ac50b58169026c8a4f06d090e2abea26843e43264fb4da1f63824a22ac0b4705da4f0353639edd918c200b6f9fc1b9039afc60b25715fdb"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "GO:0014047",
      "id": "9dc08aca95fc1a5449b78c593e218d70cc16b3b85eef565271f286fc2d9fbd2efd3a07e8a3002d6bb227b016abdb2450704785c8678073ac7b99a1514c871507"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "GO:0015871",
      "id": "a98eb8f65a69b02773ef64c963d80baa151cb109f5e967bb51bdd8e6d7562bba66e55c6eab70448acd4309045f599cfdb46173defa7d4b227f86e843ab6a0c94"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "GO:0035249",
      "id": "db6758fbdf7639161f1926bc542aa0b4d14cb2a5f2d4e546073f3560912ee24bf12db18dad1bbfdf6add13fd3d6d504dc6805fb10a09ffa3801da47e7e8121d7"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "GO:0051935",
      "id": "db76ba88f08abc4f1450c903d09de2ac00cd9eb7cc6912ec5a448eb39c0651b56939d246b2c83f3861ebcff5ea7ec478e26cf65f134d1df583ba5b3655a635f3"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "GO:0070997",
      "id": "6606d41671b2fa2244f4d46b786c8dba08bd7249e637288db7d852bd2dbc50fabac2b6df583fd67c7b27d2b1b3defb810e64abe1770a21504459ad13c79ae44e"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "MESH",
      "name": "D009435",
      "id": "088b940359982d2aa158d2a77a5d985460ad448f901d23c198a0efea9583d238b2a18ce712d54e8edd3369244deb1253d26b235f28839db38fec18f3dcad3e01"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "MESH",
      "name": "D017774",
      "id": "43f9e992b9a1a7d4042c2044cbd21f4ba3b86b461e35cfe662a0a8fbeddd4f14e617d31a38152841899c01cbbebf13eece9cba9c598a2677c37e26b115ecdec7"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "calcium(2+)",
          "id": "4fb8648e4c5fea95cea6a46291d28175bba677d8b6fa8d607b1febef51c8370cbc1ff98d09312dc418ff31d04177d26f231d4f0a1a963f43fbc29cfb3269d3c9"
        },
        {
          "function": "Protein",
          "namespace": "GFAM",
          "name": "Glutamate ionotropic receptor NMDA type subunits",
          "id": "29ba27bf8a73e82ca127ff15cacef709ca5ace693b4fa6e454716ed3e12ca06aef2dda0a21d01b187cf5f212cc5d8737edf1286ebd749aff0600ab10febfc806"
        }
      ],
      "id": "80d103d79dc1790f4fbf85a16994da82461d1abe8c6b48b787f4b4c5c161854d18ce66905ae7109f7006ac3195b131b30dc51fd49f959e571fc81c3033c95689"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "magnesium(2+)",
          "id": "5e2de80f196789c60a949cec716bb15f3f5b418c54919e7f81cfb6a8915ec12e154d6b6fa364751e8b8e5240f419f7dc76e4f27ec7ae56d57bb125a93f071f47"
        },
        {
          "function": "Protein",
          "namespace": "GFAM",
          "name": "Glutamate ionotropic receptor NMDA type subunits",
          "id": "29ba27bf8a73e82ca127ff15cacef709ca5ace693b4fa6e454716ed3e12ca06aef2dda0a21d01b187cf5f212cc5d8737edf1286ebd749aff0600ab10febfc806"
        }
      ],
      "id": "6b8eafd206411f793cc2b1b9f013dcbfd5e3627aca78885b1b7baa90a186d7544192c9aa93bca81d8a2cf9663cdc54275c828c68d616ba7f11658f69d04a3f27"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "acetylcholine",
          "id": "bae5841bb74f1e9eb73cd433cda657927031217c24e17f21bb2975128d1d9be4dc899448ede71d9aa18224145a1681b90b33287454eabf938f405bc1b8894b62"
        },
        {
          "function": "Protein",
          "namespace": "MESH",
          "name": "D011950",
          "id": "a750a673a4b522533145d8c46422ef642a876b3bd427600869f21b0ea6e6b43022b06b2082cae3f76080d4003322d741375ebcb9b89ead7364489e910a5e47c6"
        }
      ],
      "id": "9959ebdbe9c891796b42d6a9c5e99bfd701ea43f18ca07ea323b31683e441a2d6a3d0d139b8bbddc772730b3c979c2e7a37fabd7d4d7e2d43bd997363552d11d"
    },
    {
      "function": "Composite",
      "members": [
        {
          "function": "Protein",
          "namespace": "MESH",
          "name": "D011950",
          "id": "a750a673a4b522533145d8c46422ef642a876b3bd427600869f21b0ea6e6b43022b06b2082cae3f76080d4003322d741375ebcb9b89ead7364489e910a5e47c6"
        },
        {
          "function": "Protein",
          "namespace": "MESH",
          "name": "D017470",
          "id": "f8b9d9e37c2bea5b75676385fb361a2bba138d6e57c290364285af43ee8480b9caf7e27f05819da3072533be5b168d3943bec1873131e9809ab7a1fb81177b17"
        }
      ],
      "id": "20283bc5e714549096d2c7d64f8393ced14b17df176a9e93513f2b5b4279a439a7ff2f73c9d38bcb65220bba8290255921c91a550da3c3a1693a225fbd43c2b7"
    },
    {
      "function": "Protein",
      "namespace": "GFAM",
      "name": "Glutamate ionotropic receptor NMDA type subunits",
      "id": "29ba27bf8a73e82ca127ff15cacef709ca5ace693b4fa6e454716ed3e12ca06aef2dda0a21d01b187cf5f212cc5d8737edf1286ebd749aff0600ab10febfc806"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHAT",
      "id": "83616fc651645c99c1241b56d867a50ae4c018175bde3ba565013689e69f634139b6a62407ad56c90279b66bb2ed0f021686ef2123872c34ad71eb747efce213"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "GLS",
      "id": "564efa0fae943642ee53ef50d6d4131dc3b31b1345bbd492a0028981f9a1f95aa0beaf854c5f6aa21b908cf535f738655330d84793c73e59ff52097b79dbb2b9"
    },
    {
      "function": "Protein",
      "namespace": "MESH",
      "name": "D011950",
      "id": "a750a673a4b522533145d8c46422ef642a876b3bd427600869f21b0ea6e6b43022b06b2082cae3f76080d4003322d741375ebcb9b89ead7364489e910a5e47c6"
    },
    {
      "function": "Protein",
      "namespace": "MESH",
      "name": "D017470",
      "id": "f8b9d9e37c2bea5b75676385fb361a2bba138d6e57c290364285af43ee8480b9caf7e27f05819da3072533be5b168d3943bec1873131e9809ab7a1fb81177b17"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D000544",
      "id": "7b9cf1c7ea7ae87bbeaadab15ab82e2b54cc85a10079afdb10d56f83a9d7fd536cecf3a4774fa80695526878d7e53737f273bf9418db7c86929ff600291fd8cf"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D003071",
      "id": "e0805a91d1f32864206cf22865b0ef84d41f10d8c2aa54424e24b32c0b7e746897cb483e8057972a9569cdad8a61699fe9cf487ccd93d30f340a553efdd77013"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D003704",
      "id": "4a36ba330ff42ab7ce3f2b414a707f71bfde84395078b0fd68d8fca7ffbc0bc9f0e74e320e9a3a26788f17b154cc50a08e6b506c8e910532f89a1c837f251bbd"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D007858",
      "id": "8eeafbcea8f40f1b46bf3dff7eaf8f8da207944cd70ae20bbc2acffb4b63c4d4cc03289d34a601c14231b28e3e6c5be86ab4cd90edd8b019c597af6212e60046"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D008568",
      "id": "e477d196c4693402ebf4c644e177bdadc83b6d1bb03e35486d798e9c208d61b72e9c78b7119e786713f2e9c4245299a385d456b46375ade63992cb3ae26ca4d5"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D013850",
      "id": "821dca501c6013c80408de73fe27e992578f26d910d95356df8569f2f7aa58a1cca5575e7f23d15470c638e2d3fee1c3ba0e355a61d370d0974417e21430bc97"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D016874",
      "id": "374191e01f2a7a45f281068924e97a3c6e619b33035d252a6e3db69b5372b9c6a6debdc9d01d07662c0e2ff2d979e29524ec29d20ccddbfd0595544258271ecf"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D058225",
      "id": "57fd983c3b4355ab5d48d9f22714190313dd4d486c12fa9e15fb06686ae551ec367274c7ba60e22deb098f72c31d2fa25f721f99996aca1fe6c446d919fb69b5"
    }
  ],
  "links": [
    {
      "line": 54,
      "relation": "association",
      "evidence": "From the perspective of brain histopathology, Alzheimer's disease has three characteristic features—the appearance of beta-amyloid plaques, the presence of neurofibrillary tangles, and the loss of neuronal cells",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 32,
      "target": 38,
      "key": "d2f85b0f09e45ae4602c5160ecfe95db19f1187d704659905b1d23340278d7ef8e7892668ec85ef916a40d1442b1f52124c791784851e6f4335ec42b44e48d3b"
    },
    {
      "line": 56,
      "relation": "association",
      "evidence": "From the perspective of brain histopathology, Alzheimer's disease has three characteristic features—the appearance of beta-amyloid plaques, the presence of neurofibrillary tangles, and the loss of neuronal cells",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 32,
      "target": 39,
      "key": "90ec1ff7ff1c47555bbaf1cd7cb58c0231280cd60b789dbb94cb9191ff21bffdb43afe5f6985df6688c69ae2d4cba2b4b0af57462687c28bddc675f2442ae8e6"
    },
    {
      "line": 58,
      "relation": "association",
      "evidence": "From the perspective of brain histopathology, Alzheimer's disease has three characteristic features—the appearance of beta-amyloid plaques, the presence of neurofibrillary tangles, and the loss of neuronal cells",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 32,
      "target": 20,
      "key": "0126b9c92054d5a4b83d3e5d5c34fe7547e07e3478eab6a4ab2860ec07808292dd06b280044ec8d3e6ddb2b18ed12b931dc1e15a228aa822bb3af831674840de"
    },
    {
      "line": 70,
      "relation": "decreases",
      "evidence": "Although the loss of neurons leads to deficits in neurotransmission, even neurons that are not dead may exhibit impaired neurotransmission in Alzheimer's disease",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 32,
      "target": 21,
      "key": "733240d2c86dc3eb2da21d83343e999b6d7746f2918ec819bfde32985321056bfbc16a96bf1745ebfb412bd04a04948ebdfc66228dffc99129e1f9402ee68dfe"
    },
    {
      "line": 85,
      "relation": "decreases",
      "evidence": "Among the systems affected in patients with Alzheimer's disease are the cholinergic and glutamatergic neurotransmission systems. These two systems play key roles in cognition and, as a result, contemporary pharmacologic agents used in the treatment of Alzheimer's disease are designed to restore their functioning",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 32,
      "target": 14,
      "key": "d394c95a98c95571255683628804068686a42795d9f3c6ed6de306d758d5622fb08ce660fb55b5d35608e93c4160d8f24b98827d199431d2b10ef1ea8c24b493"
    },
    {
      "line": 87,
      "relation": "decreases",
      "evidence": "Among the systems affected in patients with Alzheimer's disease are the cholinergic and glutamatergic neurotransmission systems. These two systems play key roles in cognition and, as a result, contemporary pharmacologic agents used in the treatment of Alzheimer's disease are designed to restore their functioning",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 32,
      "target": 18,
      "key": "c191c9e1b57da32c2ef940f68c2dd34c18b6d408f854a248d7421f072caa613dcf50f53b61b0e74cff1f9e56cd6861d4ebf0cb6099b1eae7ffeefd4c9472ee0f"
    },
    {
      "line": 105,
      "relation": "decreases",
      "evidence": "For example, the activity of choline acetyltransferase, the enzyme that catalyzes the synthesis of ACh from choline and acetyl coenzyme A, is reduced to 35% to 50% of normal levels in Alzheimer's disease",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "object": {
        "modifier": "Activity",
        "effect": {
          "namespace": "bel",
          "name": "cat"
        }
      },
      "source": 32,
      "target": 28,
      "key": "dafe7fad315ca10e1d37e76205a7bd99773d50e8011c821af001a6979f4f482b41bdabf0057fa5637c370eaa288f98dd9dfdca9dfa6e6a340428d5499f8d7189"
    },
    {
      "line": 121,
      "relation": "decreases",
      "evidence": "Furthermore, synaptic reuptake of choline, which is essential for the synthesis of ACh molecules that are to be released into the synaptic cleft in subsequent rounds of neurotransmission, is reduced to -60% of normal levels in Alzheimer's disease, and direct measurement reveals that levels of ACh synthesis are reduced by one half in affected patients.",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 32,
      "target": 17,
      "key": "bb6f68b5b7d65989217c1b28d4a3da1d4e36dd57a119f3630d192ada3210c5549163369e457ebce28ad077cfb70a0aa866541fad7a43e5b2a1c7f59fdc098c62"
    },
    {
      "line": 123,
      "relation": "decreases",
      "evidence": "Furthermore, synaptic reuptake of choline, which is essential for the synthesis of ACh molecules that are to be released into the synaptic cleft in subsequent rounds of neurotransmission, is reduced to -60% of normal levels in Alzheimer's disease, and direct measurement reveals that levels of ACh synthesis are reduced by one half in affected patients.",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 32,
      "target": 15,
      "key": "1bc560209993a04f0b66c9b25d49846c270c8b267714a86743711f90db0ede011973d5238a4b34091c110906297aa6dac5a57055280e3b9529ecd7f170dde21e"
    },
    {
      "line": 144,
      "relation": "causesNoChange",
      "evidence": "Despite the various cholinergic abnormalities seen in Alzheimer's disease, ACh receptor systems remain relatively unaltered in affected patients.8",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "source": 32,
      "target": 30,
      "key": "deb0e82cf418aeac17acda683b1cf6338a91bf2eb99616a2d1aa216c8336ec729988409992f0e44d708861b64d5ca5aac87820e56ea8b18812cd95a5c1711950"
    },
    {
      "line": 222,
      "relation": "decreases",
      "evidence": "In patients with Alzheimer's disease, available evidence points to a disruption in the glutamatergic neurotransmission cycle at the point of glial cell reuptake of free glutamate from the synapse. Neuropathologic studies have documented reduced levels of glutamate reuptake in the frontal and temporal cortices of patients with Alzheimer's disease,10 possibly due to oxidative modification of the glutamate transporter 1 molecule. Furthermore, diminished uptake by vesicular glutamate transporter has been reported in patients with Alzheimer's disease",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        },
        "MeSHAnatomy": {
          "Temporal Lobe": true,
          "Frontal Lobe": true
        },
        "Cell": {
          "glial cell": true
        }
      },
      "source": 32,
      "target": 19,
      "key": "c0beeef82d7c175be6fdac9bc0a494eccc7a2f4a3b5860978d291f9748950e50f9c35af63e715b4e91f8ea8a2a4a7032f0d67276f5bf4aef4bf4fcff81003909"
    },
    {
      "line": 223,
      "relation": "decreases",
      "evidence": "In patients with Alzheimer's disease, available evidence points to a disruption in the glutamatergic neurotransmission cycle at the point of glial cell reuptake of free glutamate from the synapse. Neuropathologic studies have documented reduced levels of glutamate reuptake in the frontal and temporal cortices of patients with Alzheimer's disease,10 possibly due to oxidative modification of the glutamate transporter 1 molecule. Furthermore, diminished uptake by vesicular glutamate transporter has been reported in patients with Alzheimer's disease",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        },
        "MeSHAnatomy": {
          "Temporal Lobe": true,
          "Frontal Lobe": true
        },
        "Cell": {
          "glial cell": true
        }
      },
      "source": 32,
      "target": 16,
      "key": "3547af790a3820be8d8a91b1c23c95caaf62053628720bb3ae88527787c93829321c1cc9aff83f3cf002f6517c824081f588a732e6ba6373ebff11bc689d7e96"
    },
    {
      "line": 257,
      "relation": "decreases",
      "evidence": "Second, because of this background signal, as well as the fact that neurons are left with smaller amounts of neurotransmitter to release into the synapse during neuronal firing, the 'peak signal'—the difference between synaptic glutamate concentration during neuronal activity and synaptic glutamate concentration under resting conditions—is attenuated, leading to suboptimal neurotransmission as exemplified by a lack of long-term potentiation (LTP)",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Temporal Lobe": true,
          "Frontal Lobe": true
        },
        "Cell": {
          "glial cell": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 32,
      "target": 16,
      "key": "ab3c6eaa8d5171030f376fd4d45275f9f5eec7b19005d51417d10a781777d38fffe4dfe0e5c14aa7c2d885720c1224a9dc739f06de388fdca1d6736481c8275f"
    },
    {
      "line": 258,
      "relation": "decreases",
      "evidence": "Second, because of this background signal, as well as the fact that neurons are left with smaller amounts of neurotransmitter to release into the synapse during neuronal firing, the 'peak signal'—the difference between synaptic glutamate concentration during neuronal activity and synaptic glutamate concentration under resting conditions—is attenuated, leading to suboptimal neurotransmission as exemplified by a lack of long-term potentiation (LTP)",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Temporal Lobe": true,
          "Frontal Lobe": true
        },
        "Cell": {
          "glial cell": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 32,
      "target": 22,
      "key": "d706426ad8c91b3f155d3501ed0741597dcc7657bde90be056370a2055a47f158e460d09a6999cfcb32b74244922a0140a223585bbeb02189569fef3c79e84ce"
    },
    {
      "line": 272,
      "relation": "decreases",
      "evidence": "It is believed that LTP, which can persist at a given synapse for periods ranging from hours to months, models the processes of learning and memory, and a number of studies have demonstrated a loss of LTP in animal models of Alzheimer's disease.",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Temporal Lobe": true,
          "Frontal Lobe": true
        },
        "Cell": {
          "glial cell": true
        }
      },
      "source": 32,
      "target": 22,
      "key": "e64c7a1a5a8fd16f054bdfe1ff720ed9b03404f54411c3334617fd4f9d97e8829d8d767ef811eaa728d7a7bbfc05e0e09476024a0d8bc73f1ab08f1bd698008f"
    },
    {
      "line": 332,
      "relation": "decreases",
      "evidence": "In Alzheimer's disease, however, it is believed that Mg2+ is displaced from the NMDA receptor calcium channel even under resting conditions, due to the elevated levels of glutamate that are present in the synapse at all times.13 It has been hypothesized that this constant activation of NMDA receptors leads to neuronal overactivity while also contributing to an unfavorable signal-to-noise ratio during glutamatergic neurotransmission and, hence, to the absence of LTP.",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 32,
      "target": 24,
      "key": "22863310a4caf79d327966fd29340df6a6b3611110da37e5d37ee3b6184906cdc7dc88c84dc82b87466d4033666371036a31ecf6c27a436b5fb54dafb5a309c3"
    },
    {
      "line": 54,
      "relation": "association",
      "evidence": "From the perspective of brain histopathology, Alzheimer's disease has three characteristic features—the appearance of beta-amyloid plaques, the presence of neurofibrillary tangles, and the loss of neuronal cells",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 38,
      "target": 32,
      "key": "e4958ae5b4ffc8145e7f3b5f882bbb28431152f8584ed51df08a5770d35a6a1449cde4aae26d4a4d0a441ed6cc19c558fdc58ae3d149b7c72c2dc2f7ed5b1019"
    },
    {
      "line": 56,
      "relation": "association",
      "evidence": "From the perspective of brain histopathology, Alzheimer's disease has three characteristic features—the appearance of beta-amyloid plaques, the presence of neurofibrillary tangles, and the loss of neuronal cells",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 39,
      "target": 32,
      "key": "14e056b4d642c120a5c0a5f0c56f9838be4e9607bf25b673b3d9c233cbf90722ab2014b33664e2af17d3a73afc33f1068ef6b7644cb75228c69c71959072a0f1"
    },
    {
      "line": 58,
      "relation": "association",
      "evidence": "From the perspective of brain histopathology, Alzheimer's disease has three characteristic features—the appearance of beta-amyloid plaques, the presence of neurofibrillary tangles, and the loss of neuronal cells",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 20,
      "target": 32,
      "key": "3d1b16870120601e0f09a1cac4c4adc06ad5efcf6c04dbe41cfe5e458f03664027883007438096cab60ff788d3a890cba50bd1fe9635bc3bc0bda534bcdd2fe2"
    },
    {
      "line": 238,
      "relation": "association",
      "evidence": "First, the presence of elevated neurotransmitter levels in the synapse under resting conditions can be thought of as a constant 'background signal,' leading to chronic low-level activation of glutamatergic receptors on postsynaptic neurons and possibly neuronal death.",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        },
        "MeSHAnatomy": {
          "Temporal Lobe": true,
          "Frontal Lobe": true
        },
        "Cell": {
          "glial cell": true
        },
        "CellStructure": {
          "Post-Synaptic Density": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 20,
      "target": 31,
      "key": "6ad43c1c8ec12cd97a12ff7eb710ccf43865a302d2005943e78ed1ab9c8765c0ecc18d7a67412c9e6c9c4cdfb02ebbef25072bd06f53afb2bdcab24d62e1cd82"
    },
    {
      "line": 91,
      "relation": "association",
      "evidence": "Among the systems affected in patients with Alzheimer's disease are the cholinergic and glutamatergic neurotransmission systems. These two systems play key roles in cognition and, as a result, contemporary pharmacologic agents used in the treatment of Alzheimer's disease are designed to restore their functioning",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 14,
      "target": 33,
      "key": "af1a8529a8c78f3cc894459c611f206da040f1cbf6e02c4ddf0edf37468551aac7fecad3f58b07926f2d8f023d7b93929ad99643c7d1b73bb2ed85da3f1d51f2"
    },
    {
      "line": 367,
      "relation": "association",
      "evidence": "Glutamatergic and cholinergic abnormalities are strongly correlated with cognitive deterioration in Alzheimer's disease, and both types of abnormalities have been hypothesized to have a causative role in this deterioration. The two major classes of agents used to treat cognitive symptoms of Alzheimer's disease are ChEIs and NMDA receptor antagonists.",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 14,
      "target": 33,
      "key": "3695d16d2e158b47adae2092c20a09c19b39900b00f5ccdbd86c80d7465daef8a023357357bfb1f480824528fde2d2164389d31e7caa363d5494cba5ba8b0c33"
    },
    {
      "line": 378,
      "relation": "association",
      "evidence": "ChEIs are believed to target cholinergic abnormalities in Alzheimer's disease, although there is evidence indicating that their therapeutic effect may be via the glutamatergic system. NMDA receptor antagonists, in contrast, are believed to target the glutamatergic system directly",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "source": 14,
      "target": 8,
      "key": "b2b428b0653dd22cd7f931f93ee745defacfce1ca8a435b5f929555170efd8c51da7ec59f887b4a8f7d0fc63e44d2fca3ed19815290559618df8fc0ac9f892eb"
    },
    {
      "line": 90,
      "relation": "association",
      "evidence": "Among the systems affected in patients with Alzheimer's disease are the cholinergic and glutamatergic neurotransmission systems. These two systems play key roles in cognition and, as a result, contemporary pharmacologic agents used in the treatment of Alzheimer's disease are designed to restore their functioning",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 18,
      "target": 33,
      "key": "69b5b5873bcc528fa64afdba67a0dce640753a3cd8a04cea74fea25dc49376207383259df1fad69e57928ab903abbc3aba48f7c70c68f7089bb216326aa9f8da"
    },
    {
      "line": 366,
      "relation": "association",
      "evidence": "Glutamatergic and cholinergic abnormalities are strongly correlated with cognitive deterioration in Alzheimer's disease, and both types of abnormalities have been hypothesized to have a causative role in this deterioration. The two major classes of agents used to treat cognitive symptoms of Alzheimer's disease are ChEIs and NMDA receptor antagonists.",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 18,
      "target": 33,
      "key": "2aadf11fba17e53505cc7f1eff557dbfe820f497c9d16045164394a79efb40713044c10536b5757c88624f765aa7d90fadbce67093e651937d8c9b8331be7fa4"
    },
    {
      "line": 198,
      "relation": "increases",
      "evidence": "Synaptic glutamate concentration is promptly restored to normal levels, however, through the rapid uptake of unbound glutamate molecules by nearby glial cells, which subsequently convert these glutamate molecules to glutamine. The resulting glutamine molecules are then recycled to the neurons, and the cycle of glutamatergic signaling begins anew",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Cell": {
          "glial cell": true
        }
      },
      "source": 18,
      "target": 19,
      "key": "fd36a8634d6487ca5e7ba04fa2839d6398e6b41009f07f04193f0de9e8752c4fa492eadb8a39c58100f5c30088230c4202c19227e44b2389eded39c9bfd65bed"
    },
    {
      "line": 379,
      "relation": "association",
      "evidence": "ChEIs are believed to target cholinergic abnormalities in Alzheimer's disease, although there is evidence indicating that their therapeutic effect may be via the glutamatergic system. NMDA receptor antagonists, in contrast, are believed to target the glutamatergic system directly",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "source": 18,
      "target": 0,
      "key": "cc04aa48b43317cae6306969ebbad4f8680006edeff02bd858d30e3b91fcc44d95ca0e7c1e2acbab2f64546b2d20155649a1ce8c024daa9d1e2d0233bf31d1cb"
    },
    {
      "line": 90,
      "relation": "association",
      "evidence": "Among the systems affected in patients with Alzheimer's disease are the cholinergic and glutamatergic neurotransmission systems. These two systems play key roles in cognition and, as a result, contemporary pharmacologic agents used in the treatment of Alzheimer's disease are designed to restore their functioning",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 33,
      "target": 18,
      "key": "ca202091dab5a98fdba198b2c6fe39e6a1be306be3a99567e52319a0c02ab2ef98e070de9608035c014f316890dbf0cb239366d9a93037b53045e8ded2c6c296"
    },
    {
      "line": 366,
      "relation": "association",
      "evidence": "Glutamatergic and cholinergic abnormalities are strongly correlated with cognitive deterioration in Alzheimer's disease, and both types of abnormalities have been hypothesized to have a causative role in this deterioration. The two major classes of agents used to treat cognitive symptoms of Alzheimer's disease are ChEIs and NMDA receptor antagonists.",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 33,
      "target": 18,
      "key": "1dcf1839aba41aa331eed9b1ff50f058ed861fc93ff94b210531b80754ca165c8d3a2c59b9754d388baff4d073e369f626f01bf00c519ff2cd68bcc90d99dd55"
    },
    {
      "line": 91,
      "relation": "association",
      "evidence": "Among the systems affected in patients with Alzheimer's disease are the cholinergic and glutamatergic neurotransmission systems. These two systems play key roles in cognition and, as a result, contemporary pharmacologic agents used in the treatment of Alzheimer's disease are designed to restore their functioning",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 33,
      "target": 14,
      "key": "fc57bae359b27aac06f55ff34d1b693c38fc0d6a7abacd9416ef20c3e80d4d2bf04d4f810a06b4e215c9896ec5090952e7f8a096a6824f55dce8132a8c0520d0"
    },
    {
      "line": 367,
      "relation": "association",
      "evidence": "Glutamatergic and cholinergic abnormalities are strongly correlated with cognitive deterioration in Alzheimer's disease, and both types of abnormalities have been hypothesized to have a causative role in this deterioration. The two major classes of agents used to treat cognitive symptoms of Alzheimer's disease are ChEIs and NMDA receptor antagonists.",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 33,
      "target": 14,
      "key": "7821565ebf69ea475dceb77d215850c9fc5fdd2878e497b509a129a7bba57c6182ed7e7539bc99961470b578e24484ccc465fd307aeadaa41bcd7ed711121d88"
    },
    {
      "line": 101,
      "relation": "increases",
      "evidence": "For example, the activity of choline acetyltransferase, the enzyme that catalyzes the synthesis of ACh from choline and acetyl coenzyme A, is reduced to 35% to 50% of normal levels in Alzheimer's disease",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "namespace": "bel",
          "name": "cat"
        }
      },
      "source": 28,
      "target": 5,
      "key": "a8ce83186eee88aff9d4d9498ccbf04a9eeda1093971f6b31201ab254ccb6610a94c8576ed9cd9a0f77f2d411225d8fd046a8cb73a186e566b1c70251d21da9b"
    },
    {
      "line": 304,
      "relation": "increases",
      "evidence": "Pyramidal neurons, which account for ~70% of all neurons in the neocortex, use glutamate as their primary neurotransmitter. Nonetheless, in addition to possessing glutamatergic receptors on their surface, these neurons often also possess cholinergic receptors, which are capable of receiving cholinergic inputs into the neocortex from the basal forebrain. The presence of these cholinergic receptors has been putatively linked to an important finding regarding the interaction between the cholinergic and glutamatergic neurotransmission systems. In particular, rodent studies have revealed that cholinesterase inhibitors (ChEIs) promote the release of glutamate from pyramidal neurons,16 with the proposed explanation being that ChEI administration leads to increased cortical ACh concentrations and, consequently, increased binding of ACh by cholinergic receptors on pyramidal neurons, thereby stimulating neuronal firing (ie, glutamate release).",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Neocortex": true
        },
        "Cell": {
          "pyramidal neuron": true
        },
        "Species": {
          "10116": true
        }
      },
      "source": 5,
      "target": 25,
      "key": "417fdedb62bc38d4c87565aca00512fc7a3cf5744e005e2ab474ceef0afd52db76a0aac3255d365c07f26931a842fb10330a8d23cf62d00c59b1fd589038f042"
    },
    {
      "line": 135,
      "relation": "association",
      "evidence": "In fact, it has been demonstrated that decreasing levels of ACh synthesis are significantly correlated with increasing severity of dementia in patients with Alzheimer's disease (Table)",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 15,
      "target": 34,
      "key": "9fadf49594bd69b3c7d453eaf149546304c01b8c6dcb504d8ac2aed170a79e176dbce8babb4808bca976df80f2cc7dbc42391a9f9fe4d6a1e6a2dc37ccfd46b5"
    },
    {
      "line": 135,
      "relation": "association",
      "evidence": "In fact, it has been demonstrated that decreasing levels of ACh synthesis are significantly correlated with increasing severity of dementia in patients with Alzheimer's disease (Table)",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 34,
      "target": 15,
      "key": "b9cc88f603b226bdf2cb8faee1af08fda44ee6ffdea36f5e30bbf1d885db42114ee52b88afa561c7b235ccafdd11163ae0e407abab37544cfd88f6f87d5c6ced"
    },
    {
      "line": 154,
      "relation": "association",
      "evidence": "The capacity for thinking and remembering is derived from various input and output pathways between the hippocampus and the neocortex,9 and all such pathways rely on signaling mediated by the neurotransmitter glutamate. ",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "source": 37,
      "target": 9,
      "key": "997d9057be15eade3eeaf541e06fb7ae4a098e69897b095b8244d73dcac697955b73b3dbdb98bba04990ec30bc0de96b2ee4fee17a00b85c0fe3675a93b304e3"
    },
    {
      "line": 155,
      "relation": "association",
      "evidence": "The capacity for thinking and remembering is derived from various input and output pathways between the hippocampus and the neocortex,9 and all such pathways rely on signaling mediated by the neurotransmitter glutamate. ",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "source": 37,
      "target": 12,
      "key": "026892374f1a6ecf23b415ff0f9f0baff4bb06d37ac8bace9a336a20d71d1f19afc80c9826e01b06942a72d3ce30321a31a3a336d8d318ee5079b4803bd79642"
    },
    {
      "line": 156,
      "relation": "association",
      "evidence": "The capacity for thinking and remembering is derived from various input and output pathways between the hippocampus and the neocortex,9 and all such pathways rely on signaling mediated by the neurotransmitter glutamate. ",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "source": 37,
      "target": 2,
      "key": "35d3d2bb25b71a203de26d1b282a8ee542e24fe89924a341dcbd27861e86a66682919e223a81737af1c23eb8c44907ca0fc1a24ea55b098d7a64f3a2f93fc47d"
    },
    {
      "line": 154,
      "relation": "association",
      "evidence": "The capacity for thinking and remembering is derived from various input and output pathways between the hippocampus and the neocortex,9 and all such pathways rely on signaling mediated by the neurotransmitter glutamate. ",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "source": 9,
      "target": 37,
      "key": "f18d2a87c18e8355d765d3bc3db3ced555294c36d02c05ea2db4b620e64256d029f0a40917bd4ffe9a8072213bd5571668caf27fd88a2edf50de47a25c347357"
    },
    {
      "line": 158,
      "relation": "association",
      "evidence": "The capacity for thinking and remembering is derived from various input and output pathways between the hippocampus and the neocortex,9 and all such pathways rely on signaling mediated by the neurotransmitter glutamate. ",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "source": 9,
      "target": 36,
      "key": "58cfc9e144c104238d2cd765048277ee7db070f7174f13a56315f2d42d329e53ed191e48e4880c78e88c7c5755e4020ffee192140de5d64c03f047e1356718b5"
    },
    {
      "line": 155,
      "relation": "association",
      "evidence": "The capacity for thinking and remembering is derived from various input and output pathways between the hippocampus and the neocortex,9 and all such pathways rely on signaling mediated by the neurotransmitter glutamate. ",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "source": 12,
      "target": 37,
      "key": "c801fbea82db3a5bbb5d163c0b82292e6dafed1506eb2d66bafd28fdca1387b9a57a4eb0bdf6fbd8824956c997ca7fd8c2ed31e1247766418e71c8ac7fc26a52"
    },
    {
      "line": 159,
      "relation": "association",
      "evidence": "The capacity for thinking and remembering is derived from various input and output pathways between the hippocampus and the neocortex,9 and all such pathways rely on signaling mediated by the neurotransmitter glutamate. ",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "source": 12,
      "target": 36,
      "key": "69e6865ed69a966be0b62e04db196dae72579f3110c54dd7c24790556c3007799990c4d365cd95b446935514b089fcdf4ee61282006bef416ce693352ca67227"
    },
    {
      "line": 156,
      "relation": "association",
      "evidence": "The capacity for thinking and remembering is derived from various input and output pathways between the hippocampus and the neocortex,9 and all such pathways rely on signaling mediated by the neurotransmitter glutamate. ",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "source": 2,
      "target": 37,
      "key": "f4967e4691743c067221eafb06fcec7d00fc4d95ca6d15069eca70ef4822f8499c9af2b4ebb05b539af8473be0345f701510aa2b630c95ce2514b77846b3570b"
    },
    {
      "line": 160,
      "relation": "association",
      "evidence": "The capacity for thinking and remembering is derived from various input and output pathways between the hippocampus and the neocortex,9 and all such pathways rely on signaling mediated by the neurotransmitter glutamate. ",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "source": 2,
      "target": 36,
      "key": "f4d74affab2750bc1d25643580664d105076e877534479d0c6bba511d47d42d248e5d984f2ca63e2445ebdb9482de7a569e15ed5b6801fda6d1d9fbedb76c6b3"
    },
    {
      "line": 158,
      "relation": "association",
      "evidence": "The capacity for thinking and remembering is derived from various input and output pathways between the hippocampus and the neocortex,9 and all such pathways rely on signaling mediated by the neurotransmitter glutamate. ",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "source": 36,
      "target": 9,
      "key": "51c28552bbb0b13f0bddf6ab32c4b6f9657ec41db21e5b5c29ff9543d256c4c0ea44a183eb2eff37a6214aae81089a2c6eeafdfc80b7d5913d93eeb5467417b3"
    },
    {
      "line": 159,
      "relation": "association",
      "evidence": "The capacity for thinking and remembering is derived from various input and output pathways between the hippocampus and the neocortex,9 and all such pathways rely on signaling mediated by the neurotransmitter glutamate. ",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "source": 36,
      "target": 12,
      "key": "8ce3224a82552e7af1fb49d0bfceb840294c2382a941af49f9fbd93a479c798e6bc9f215bd4eb7f716a5471100520d215e27fa9327f379a8ff8390bbe6ebd2a3"
    },
    {
      "line": 160,
      "relation": "association",
      "evidence": "The capacity for thinking and remembering is derived from various input and output pathways between the hippocampus and the neocortex,9 and all such pathways rely on signaling mediated by the neurotransmitter glutamate. ",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "source": 36,
      "target": 2,
      "key": "4932141353bdd446e220db6e6e6dd6d7c904d44e748310175362ec1a4319d6e0fade6e2e19823803fd47adbef09bdc6e7cc092fb4a30ba2713ba9c0bc4d34f54"
    },
    {
      "line": 269,
      "relation": "association",
      "evidence": "It is believed that LTP, which can persist at a given synapse for periods ranging from hours to months, models the processes of learning and memory, and a number of studies have demonstrated a loss of LTP in animal models of Alzheimer's disease.",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Temporal Lobe": true,
          "Frontal Lobe": true
        },
        "Cell": {
          "glial cell": true
        }
      },
      "source": 36,
      "target": 22,
      "key": "0b25c72ce0740ae99f051a538094afade6033cf16bc1d91edf27a676116aeeb2bf870fbbe27787d97dcacb269a20693157be0fa2736bc364ab6988e96a9efc48"
    },
    {
      "line": 179,
      "relation": "directlyIncreases",
      "evidence": "In healthy individuals, the glutamatergic neurotransmission cycle begins in the mitochondria of hippocampal neurons, where the enzyme glutaminase catalyzes the conversion of glutamine to glutamate. Next, the vesicular glutamate transporter molecule mediates the packaging of these glutamate molecules into vesicles. Glutamate-containing vesicles are then released from the neuron, resulting in elevated synaptic concentrations of free glutamate, which can transmit neural signals by interacting with glutamatergic receptors on postsynaptic neurons",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true
        },
        "Cell": {
          "hippocampal neuron": true
        },
        "CellStructure": {
          "Mitochondria": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "namespace": "bel",
          "name": "cat"
        }
      },
      "source": 29,
      "target": 2,
      "key": "5680d5b549483724e90946204a9731044f9268fb4d60d65406a532b2c7afbdf0c347ae613a800f269cc023ad8771d6be61a786e8dbf29d0d828c4a54aa6c4beb"
    },
    {
      "line": 181,
      "relation": "directlyIncreases",
      "evidence": "In healthy individuals, the glutamatergic neurotransmission cycle begins in the mitochondria of hippocampal neurons, where the enzyme glutaminase catalyzes the conversion of glutamine to glutamate. Next, the vesicular glutamate transporter molecule mediates the packaging of these glutamate molecules into vesicles. Glutamate-containing vesicles are then released from the neuron, resulting in elevated synaptic concentrations of free glutamate, which can transmit neural signals by interacting with glutamatergic receptors on postsynaptic neurons",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true
        },
        "Cell": {
          "hippocampal neuron": true
        },
        "CellStructure": {
          "Mitochondria": true
        }
      },
      "source": 3,
      "target": 16,
      "key": "3f0df9c2eb9a869540a76bae290442c7837b2a4c463903e7744dbf68501e76158de7168571fa1ef03e1a9eba2bdf16fc43ac4fe081523ae724ac65b494ca4fea"
    },
    {
      "line": 236,
      "relation": "directlyIncreases",
      "evidence": "First, the presence of elevated neurotransmitter levels in the synapse under resting conditions can be thought of as a constant 'background signal,' leading to chronic low-level activation of glutamatergic receptors on postsynaptic neurons and possibly neuronal death.",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        },
        "MeSHAnatomy": {
          "Temporal Lobe": true,
          "Frontal Lobe": true
        },
        "Cell": {
          "glial cell": true
        },
        "CellStructure": {
          "Post-Synaptic Density": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 3,
      "target": 31,
      "key": "a273e8b4f991f1ef4f07ae857d9cd6e3032b52698e2acfe9a09ae7e4d59c07b9ec663b307463664011b1d093c8e575d6eb745474c3eb76c2e46cdb2d457169e8"
    },
    {
      "line": 182,
      "relation": "increases",
      "evidence": "In healthy individuals, the glutamatergic neurotransmission cycle begins in the mitochondria of hippocampal neurons, where the enzyme glutaminase catalyzes the conversion of glutamine to glutamate. Next, the vesicular glutamate transporter molecule mediates the packaging of these glutamate molecules into vesicles. Glutamate-containing vesicles are then released from the neuron, resulting in elevated synaptic concentrations of free glutamate, which can transmit neural signals by interacting with glutamatergic receptors on postsynaptic neurons",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true
        },
        "Cell": {
          "hippocampal neuron": true
        },
        "CellStructure": {
          "Mitochondria": true
        }
      },
      "source": 16,
      "target": 18,
      "key": "372daca0a2a0edd297fcefc44921d238874cb8f18bdccd470f900c4658de7d2a2c5a6f7235cf914297778db4c038fdc6f09adf4304c9a3a4091c400d07b953c1"
    },
    {
      "line": 256,
      "relation": "increases",
      "evidence": "Second, because of this background signal, as well as the fact that neurons are left with smaller amounts of neurotransmitter to release into the synapse during neuronal firing, the 'peak signal'—the difference between synaptic glutamate concentration during neuronal activity and synaptic glutamate concentration under resting conditions—is attenuated, leading to suboptimal neurotransmission as exemplified by a lack of long-term potentiation (LTP)",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Temporal Lobe": true,
          "Frontal Lobe": true
        },
        "Cell": {
          "glial cell": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 16,
      "target": 22,
      "key": "3d1bd1e75318bc1d6a2e9869c3fdc935bd97faf92128df228d96832096e18e4e96a7818a2e127c973f201fe102ad26be7e17bde1ea1d8023bdd5ec5e6dfd4e83"
    },
    {
      "line": 199,
      "relation": "increases",
      "evidence": "Synaptic glutamate concentration is promptly restored to normal levels, however, through the rapid uptake of unbound glutamate molecules by nearby glial cells, which subsequently convert these glutamate molecules to glutamine. The resulting glutamine molecules are then recycled to the neurons, and the cycle of glutamatergic signaling begins anew",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Cell": {
          "glial cell": true
        }
      },
      "source": 19,
      "target": 6,
      "key": "92455308a4301d53e6eb0301b018afb1e62bc2bd1586a0260eb828eeb64c65fd76c4bc71c3f0929ffe42f1a1a737a653c4bd3a32e7c7059a037bac962c9c18fe"
    },
    {
      "line": 201,
      "relation": "increases",
      "evidence": "Synaptic glutamate concentration is promptly restored to normal levels, however, through the rapid uptake of unbound glutamate molecules by nearby glial cells, which subsequently convert these glutamate molecules to glutamine. The resulting glutamine molecules are then recycled to the neurons, and the cycle of glutamatergic signaling begins anew",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Cell": {
          "glial cell": true
        }
      },
      "source": 6,
      "target": 13,
      "key": "84e93c4aaee560fbff7b1ef90716a3ccc46208a01dbb9f727d9333fcce361c263931222d3233f91c17ddc88b9b3cd7f0b9c92c647d36d092c2d097b9450d4888"
    },
    {
      "line": 238,
      "relation": "association",
      "evidence": "First, the presence of elevated neurotransmitter levels in the synapse under resting conditions can be thought of as a constant 'background signal,' leading to chronic low-level activation of glutamatergic receptors on postsynaptic neurons and possibly neuronal death.",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        },
        "MeSHAnatomy": {
          "Temporal Lobe": true,
          "Frontal Lobe": true
        },
        "Cell": {
          "glial cell": true
        },
        "CellStructure": {
          "Post-Synaptic Density": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 31,
      "target": 20,
      "key": "b0798a8b3aba224a4fe9f692dfcbf6f1f64b587862635ea8f0b0236cf7d49dff856fad0663bef9e49cb8b6718e59f74f0298436fb1b7617fa3b1d79d92f69cd2"
    },
    {
      "line": 269,
      "relation": "association",
      "evidence": "It is believed that LTP, which can persist at a given synapse for periods ranging from hours to months, models the processes of learning and memory, and a number of studies have demonstrated a loss of LTP in animal models of Alzheimer's disease.",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Temporal Lobe": true,
          "Frontal Lobe": true
        },
        "Cell": {
          "glial cell": true
        }
      },
      "source": 22,
      "target": 36,
      "key": "95bbe0dcd75894ac1f003b937fb8c3f4377c6031eb6e0c53a33b1b887b198c4cf593a44b8f45532b8965a2301d4fe00893795f393c90b280eda8121542a5f087"
    },
    {
      "line": 271,
      "relation": "association",
      "evidence": "It is believed that LTP, which can persist at a given synapse for periods ranging from hours to months, models the processes of learning and memory, and a number of studies have demonstrated a loss of LTP in animal models of Alzheimer's disease.",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Temporal Lobe": true,
          "Frontal Lobe": true
        },
        "Cell": {
          "glial cell": true
        }
      },
      "source": 22,
      "target": 35,
      "key": "6969fa1a7c6bd74b955dbfb580359481d193c139882ac856831be1dc84580ac44b0e1a0833155cee749d8920dd433f50747207c4bd56b199c5286fd3b50efe1b"
    },
    {
      "line": 271,
      "relation": "association",
      "evidence": "It is believed that LTP, which can persist at a given synapse for periods ranging from hours to months, models the processes of learning and memory, and a number of studies have demonstrated a loss of LTP in animal models of Alzheimer's disease.",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Temporal Lobe": true,
          "Frontal Lobe": true
        },
        "Cell": {
          "glial cell": true
        }
      },
      "source": 35,
      "target": 22,
      "key": "67c6168e299199d8b59150ac6e62f71bc04245dfe57985d28ab0340c5749c68444caa6d12bc770d4e73511e9d9a19d01f6ca918cb49d766c7c4b5f89593ba9c0"
    },
    {
      "line": 298,
      "relation": "association",
      "evidence": "Pyramidal neurons, which account for ~70% of all neurons in the neocortex, use glutamate as their primary neurotransmitter. Nonetheless, in addition to possessing glutamatergic receptors on their surface, these neurons often also possess cholinergic receptors, which are capable of receiving cholinergic inputs into the neocortex from the basal forebrain. The presence of these cholinergic receptors has been putatively linked to an important finding regarding the interaction between the cholinergic and glutamatergic neurotransmission systems. In particular, rodent studies have revealed that cholinesterase inhibitors (ChEIs) promote the release of glutamate from pyramidal neurons,16 with the proposed explanation being that ChEI administration leads to increased cortical ACh concentrations and, consequently, increased binding of ACh by cholinergic receptors on pyramidal neurons, thereby stimulating neuronal firing (ie, glutamate release).",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Neocortex": true
        },
        "Cell": {
          "pyramidal neuron": true
        }
      },
      "source": 11,
      "target": 26,
      "key": "f32a0d324f9e029fcfe1d180defba269c239e2501dfa23f6b3b2e8b0beb8a07398569fe0c54c27cf4f405de734de5a7b8bce6dd940f87184cd743906d06f84a7"
    },
    {
      "relation": "hasComponent",
      "source": 26,
      "target": 30,
      "key": "57269a58460cc533bcb0f0d242a93180fe2123da131a854ebd07ce6c598b7a182b489906f4e51fe795e022d95b20e59a207bae83679f513a21eb3e9cbfc3215c"
    },
    {
      "relation": "hasComponent",
      "source": 26,
      "target": 31,
      "key": "3fa714a4aceed239c54aba8e297a1f52f3e878f0ee40462c81e0d6173f502c40b537d3ee60bf132af4c950ae173d2c3764b60e56756cdaf5cdd6892f30d91837"
    },
    {
      "line": 298,
      "relation": "association",
      "evidence": "Pyramidal neurons, which account for ~70% of all neurons in the neocortex, use glutamate as their primary neurotransmitter. Nonetheless, in addition to possessing glutamatergic receptors on their surface, these neurons often also possess cholinergic receptors, which are capable of receiving cholinergic inputs into the neocortex from the basal forebrain. The presence of these cholinergic receptors has been putatively linked to an important finding regarding the interaction between the cholinergic and glutamatergic neurotransmission systems. In particular, rodent studies have revealed that cholinesterase inhibitors (ChEIs) promote the release of glutamate from pyramidal neurons,16 with the proposed explanation being that ChEI administration leads to increased cortical ACh concentrations and, consequently, increased binding of ACh by cholinergic receptors on pyramidal neurons, thereby stimulating neuronal firing (ie, glutamate release).",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Neocortex": true
        },
        "Cell": {
          "pyramidal neuron": true
        }
      },
      "source": 26,
      "target": 11,
      "key": "3efbde6d8250eeb833ded579fc0b8b06d8510553af8230a70b8aa7f0276bfbf0b3e08c6d4946f51d490dd0c917648c32bca0673cd3fc591342ace6e02bb23423"
    },
    {
      "line": 302,
      "relation": "increases",
      "evidence": "Pyramidal neurons, which account for ~70% of all neurons in the neocortex, use glutamate as their primary neurotransmitter. Nonetheless, in addition to possessing glutamatergic receptors on their surface, these neurons often also possess cholinergic receptors, which are capable of receiving cholinergic inputs into the neocortex from the basal forebrain. The presence of these cholinergic receptors has been putatively linked to an important finding regarding the interaction between the cholinergic and glutamatergic neurotransmission systems. In particular, rodent studies have revealed that cholinesterase inhibitors (ChEIs) promote the release of glutamate from pyramidal neurons,16 with the proposed explanation being that ChEI administration leads to increased cortical ACh concentrations and, consequently, increased binding of ACh by cholinergic receptors on pyramidal neurons, thereby stimulating neuronal firing (ie, glutamate release).",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Neocortex": true
        },
        "Cell": {
          "pyramidal neuron": true
        },
        "Species": {
          "10116": true
        }
      },
      "source": 8,
      "target": 16,
      "key": "e52428f30f82b74d03fc3aece0fb9e2237d15b83033d67293c3452afc8b0e11cde063ca757d52fad5e5877d2ab2ccdefb30349e287edd65627682901cf843fbe"
    },
    {
      "line": 397,
      "relation": "increases",
      "evidence": "With regard to the glutamatergic system, studies suggest that ChEIs may stimulate the release of glutamate from pyramidal neurons during normal neuronal activity, while NMDA receptor antagonists are believed to block the abnormal neuronal activity that results from the presence of excess glutamate in the synapse under resting conditions. Thus, ChEIs and NMDA receptor antagonists appear to have complementary effects, as the former enhance the signals received by postsynaptic neurons during normal neurotransmission, and the latter diminish the background 'noise' that is constantly being detected by those same receptors.",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Cell": {
          "pyramidal neuron": true
        }
      },
      "source": 8,
      "target": 16,
      "key": "0b7e8d1cab51e890e4e5d1a2ee37e71aa63fdae2c04ac2beb9cd7b5fd5a2f3e53e0b939901a8c62cc045b877296b69fccf8d8d73e800087ade67f4b48bff3c5f"
    },
    {
      "line": 303,
      "relation": "increases",
      "evidence": "Pyramidal neurons, which account for ~70% of all neurons in the neocortex, use glutamate as their primary neurotransmitter. Nonetheless, in addition to possessing glutamatergic receptors on their surface, these neurons often also possess cholinergic receptors, which are capable of receiving cholinergic inputs into the neocortex from the basal forebrain. The presence of these cholinergic receptors has been putatively linked to an important finding regarding the interaction between the cholinergic and glutamatergic neurotransmission systems. In particular, rodent studies have revealed that cholinesterase inhibitors (ChEIs) promote the release of glutamate from pyramidal neurons,16 with the proposed explanation being that ChEI administration leads to increased cortical ACh concentrations and, consequently, increased binding of ACh by cholinergic receptors on pyramidal neurons, thereby stimulating neuronal firing (ie, glutamate release).",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Neocortex": true
        },
        "Cell": {
          "pyramidal neuron": true
        },
        "Species": {
          "10116": true
        }
      },
      "source": 8,
      "target": 5,
      "key": "e7424203277b6f02bce8104cf8a7322fc767154ff1bb65395a7e0fc05f28dba19cb82bce2ea779e2d95e1148c09602e632aa63c5a2f661db08b09e2e6ad3142c"
    },
    {
      "line": 378,
      "relation": "association",
      "evidence": "ChEIs are believed to target cholinergic abnormalities in Alzheimer's disease, although there is evidence indicating that their therapeutic effect may be via the glutamatergic system. NMDA receptor antagonists, in contrast, are believed to target the glutamatergic system directly",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "source": 8,
      "target": 14,
      "key": "9da6eb9aa28fc4504920ef199ec33562e73544df3bb348e10a56eb2d265e159d925703c9df95cce4081a694bbc7a6d39977e5b58a9f1eecc7fac9e268fba6625"
    },
    {
      "relation": "hasComponent",
      "source": 25,
      "target": 5,
      "key": "a4ffcb9b7f84daf8cd4a94fc631b2e79b6c3e1bb97786a391d76816052bda1898311ce46853e5ecce7c8b376d0bb3e96009fcb401e992d8e3a51ee1487dace0f"
    },
    {
      "line": 305,
      "relation": "increases",
      "evidence": "Pyramidal neurons, which account for ~70% of all neurons in the neocortex, use glutamate as their primary neurotransmitter. Nonetheless, in addition to possessing glutamatergic receptors on their surface, these neurons often also possess cholinergic receptors, which are capable of receiving cholinergic inputs into the neocortex from the basal forebrain. The presence of these cholinergic receptors has been putatively linked to an important finding regarding the interaction between the cholinergic and glutamatergic neurotransmission systems. In particular, rodent studies have revealed that cholinesterase inhibitors (ChEIs) promote the release of glutamate from pyramidal neurons,16 with the proposed explanation being that ChEI administration leads to increased cortical ACh concentrations and, consequently, increased binding of ACh by cholinergic receptors on pyramidal neurons, thereby stimulating neuronal firing (ie, glutamate release).",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "MeSHAnatomy": {
          "Neocortex": true
        },
        "Cell": {
          "pyramidal neuron": true
        },
        "Species": {
          "10116": true
        }
      },
      "source": 25,
      "target": 5,
      "key": "b6af77de862f3dbc43a45e462195c49b5f7a0589180c432e16758b372818fbbd44b3c6bfd4ebbfe08b7b3a33fe53589e0d276aaa7a9850d70f1e4888c308fd2c"
    },
    {
      "relation": "hasComponent",
      "source": 25,
      "target": 30,
      "key": "fa02c7c62dfb7d8d01e07787612092a4cfaee16aa25cceeeb5e72ccab58839fcf527136236e9beac17b5ba5798d11a00a29a29cdeab019fbede90198176961b8"
    },
    {
      "line": 317,
      "relation": "decreases",
      "evidence": "In individuals with normal cognitive functioning, Mg2+ blocks the passage of Ca2+ through the neuronal NMDA receptor calcium channel under resting conditions, but it is readily displaced when membrane depolarization occurs and synaptic glutamate concentrations are at peak levels (ie, when neuronal firing occurs).",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "source": 4,
      "target": 23,
      "key": "b21509de09edd6f90476f585f09dc33a5b13175a423b0275a80d863e5173bd1a0f0ed0d7ba7b04ad1d9609dd46bbc11071d0bcec9d3392f98060e5f38df9c886"
    },
    {
      "relation": "hasComponent",
      "source": 23,
      "target": 1,
      "key": "6e3ba9bbb0ce5e5394410e74cf73126c268f80ff61d138b124e54d41dc230aa2504227ca63b84027d140eb1f765a51d165e47633a6aceae975b520c9d2686bc4"
    },
    {
      "relation": "hasComponent",
      "source": 23,
      "target": 27,
      "key": "10ce52dc638abab1b7bc396d354e1ed4bfbcc679da16e03000893a20d076cb8ac327e71af1c4a9f3bd064af8291e8ea0ce08f651706e777c6510335d9b753d8c"
    },
    {
      "line": 333,
      "relation": "decreases",
      "evidence": "In Alzheimer's disease, however, it is believed that Mg2+ is displaced from the NMDA receptor calcium channel even under resting conditions, due to the elevated levels of glutamate that are present in the synapse at all times.13 It has been hypothesized that this constant activation of NMDA receptors leads to neuronal overactivity while also contributing to an unfavorable signal-to-noise ratio during glutamatergic neurotransmission and, hence, to the absence of LTP.",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 27,
      "target": 22,
      "key": "1a5578e26751daa07261831ba2daaf9a0888b8c0b36db035e835272367186ee41fd1edd58a241890897024ee3387f5c6f4d72012fc0412313ff606926ffa9443"
    },
    {
      "relation": "hasComponent",
      "source": 24,
      "target": 4,
      "key": "7d3d3ef5c6e637a95a5e3ffbc96d5a3b99be5dfebe192cd8cd9d9f66f91d3bb1b2fd4b3fa48ad2572d505f74ff9bd8aad74ca7ba8d9ae43eb6fb7cde50a891c1"
    },
    {
      "relation": "hasComponent",
      "source": 24,
      "target": 27,
      "key": "801eb157e88de948b6b6086d0e767dccca609cd6903a98cfcf2ccd1c5ff6f780bf828fa030d43bd4e4168d2b12d8a2ce9988940565241008d044cb2eb825e460"
    },
    {
      "line": 350,
      "relation": "decreases",
      "evidence": "According to the proposed hypothesis, memantine has the ability to block the passage of Ca2+ through the calcium channel even when, as in Alzheimer's disease, resting synaptic glutamate levels are abnormally high, but it is still readily displaced at peak synaptic glutamate concentrations.13 In other words, the clinical efficacy of memantine appears to stem from its ability to prevent neuronal overactivity without also hindering normal neurotransmission.",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 7,
      "target": 23,
      "key": "0cd5f4b71b29e1726b8763df57b6aa27a537a9178f1ab2ae541bca485ecaa6189b30bdc9278f2f87e90fdaf87f7f85ac7a1834332ab371ffc2951a237d55d22f"
    },
    {
      "line": 352,
      "relation": "causesNoChange",
      "evidence": "According to the proposed hypothesis, memantine has the ability to block the passage of Ca2+ through the calcium channel even when, as in Alzheimer's disease, resting synaptic glutamate levels are abnormally high, but it is still readily displaced at peak synaptic glutamate concentrations.13 In other words, the clinical efficacy of memantine appears to stem from its ability to prevent neuronal overactivity without also hindering normal neurotransmission.",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 7,
      "target": 21,
      "key": "e669b90f592712553da5ffa5785b38f89fae7684772b71b89ff8ec67b411dd893058771d30e9275579f22904dbe4fa79dd0b32f615bf531ae2522ae447b88c6b"
    },
    {
      "line": 379,
      "relation": "association",
      "evidence": "ChEIs are believed to target cholinergic abnormalities in Alzheimer's disease, although there is evidence indicating that their therapeutic effect may be via the glutamatergic system. NMDA receptor antagonists, in contrast, are believed to target the glutamatergic system directly",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "source": 0,
      "target": 18,
      "key": "e64cfb73c8ada562d0ea31f87cfa3ae8075d22dc23345d0a726d6839c5ea3310ffc523c3526e3648f5f51ced6f4a14cd75c91a4755a57d72838a8a13663215ba"
    },
    {
      "line": 399,
      "relation": "decreases",
      "evidence": "With regard to the glutamatergic system, studies suggest that ChEIs may stimulate the release of glutamate from pyramidal neurons during normal neuronal activity, while NMDA receptor antagonists are believed to block the abnormal neuronal activity that results from the presence of excess glutamate in the synapse under resting conditions. Thus, ChEIs and NMDA receptor antagonists appear to have complementary effects, as the former enhance the signals received by postsynaptic neurons during normal neurotransmission, and the latter diminish the background 'noise' that is constantly being detected by those same receptors.",
      "citation": {
        "type": "PubMed",
        "reference": "16273023"
      },
      "annotations": {
        "Cell": {
          "pyramidal neuron": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 0,
      "target": 10,
      "key": "1329e4a62207f811a69dc330a33ae9defe21f9bb232d22906fcf7ceacc96a7baf5f6fad5b3a87c66431ca18efb0e6add4aab8d19cf2a4f84e3762000d7ac9fa2"
    }
  ]
}